Market Cap
$35.0M
ELUT
ELUTIA INC.
$0.7787 ▼ -2.66%
Prev close $0.8000Market cap$35.0M
12-mo target$5.00 (+542.1%)
Insider Buying Cluster (2 insiders)High Impact Filing (7/10)4 New Institutional Positions Biotech & Drug Discovery
Snapshot
The big-picture read on ELUT right now — valuation, ownership and activity at a glance.
Cap Size
Nano Cap
Inst. Holders
18 funds
Inst. Value
$2.5M
Inst. Activity
4 buys / 2 sells
Insider Activity
$95.0K buy / $0.00 sell
Insider Net $
$95.0K
SEC Reports
4
Price chart 30d -7.3%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 1, 2026 other
Elutia Receives $8 Million Payment from Boston Scientific; Company Now Fully Funded into 2029
Elutia today announced it has received the full $8 million held in escrow in connection with the sal
Sep 10, 2026 Insider
Mills C Randal acquired via exercise 27,083 shares
PRESIDENT AND CEO
Sep 10, 2026 Insider
Williams Michelle LeRoux acquired via exercise 12,500 shares
CHIEF SCIENTIFIC OFFICER
Sep 10, 2026 Insider
Jul 31, 2026 SEC Ferguson Matthew acquired via exercise 12,500 shares
CHIEF FINANCIAL OFFICER
Elutia Inc. announced it will report second quarter 2026 financial results on August 13, 2026. No financial data or guid
PRESS-RELEASE — Impact 2/10
Jun 30, 2026 Inst.
RENAISSANCE TECHNOLOGIES LLC — DOUBLED
201,816 shares ($197.7K)
Jun 30, 2026 Inst.
Jun 16, 2026 SEC VANGUARD FIDUCIARY TRUST CO — ADD
172,446 shares ($169.0K)
Elutia Inc. filed an 8-K reporting the results of its 2026 Annual Meeting of Stockholders, where shareholders approved a
8-K — Impact 3/10
Analyst ratings buy % -2.3%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 10, 2025 | Lake Street | MAINTAIN | Buy | 45% |
| May 9, 2025 | Lake Street | MAINTAIN | Buy | 45% |
| Mar 7, 2025 | Cantor Fitzgerald | REITERATE | Overweight | 49% |
| Nov 15, 2024 | Cantor Fitzgerald | REITERATE | Overweight | 49% |
| Sep 6, 2024 | Cantor Fitzgerald | REITERATE | Overweight | 49% |
| Aug 8, 2024 | Cantor Fitzgerald | MAINTAIN | Overweight | 49% |
| Jun 21, 2024 | Lake Street | MAINTAIN | Buy | 45% |
| Jun 20, 2024 | Cantor Fitzgerald | MAINTAIN | Overweight | 49% |
| Jun 18, 2024 | Cantor Fitzgerald | MAINTAIN | Overweight | 49% |
| May 10, 2024 | Cantor Fitzgerald | MAINTAIN | Overweight | 49% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Aug 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Jul 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Jun 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| May 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Apr 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Mar 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Feb 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% |
Price targets
Where 1 covering analysts think ELUT trades over the next 12 months.
$5.00 +542.1% upside Strong Buy
Current$0.7787 Low$5.00 Median$5.00 High$5.00 1 analysts
$5.00$5.00
Analyst rating None as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
4 SEC filing reports analyzed · 0 bullish, 0 bearish, 1 mixed, 3 neutral · avg impact 4.3/10.
NEUTRALPRESS-RELEASE2/10
Elutia Inc. announced it will report second quarter 2026 financial results on August 13, 2026. No fi
Jul 31, 2026
NEUTRAL8-K3/10
Elutia Inc. filed an 8-K reporting the results of its 2026 Annual Meeting of Stockholders, where sha
Jun 16, 2026
NEUTRAL8-K5/10
Elutia reported Q1 2026 revenue of $3.1M (+6% YoY) and a GAAP net loss of $7.5M, widening from a $3.
May 14, 2026
MIXED8-K7/10
Elutia reported its 2025 financial results, highlighted by the $88 million sale of its BioEnvelope b
Mar 11, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Oct 1, 2026
other
Elutia Receives $8 Million Payment from Boston Scientific; Company Now Fully Funded into 2029
Elutia today announced it has received the full $8 million held in escrow in connection with the sale of its BioEnvelope business to Boston Scientific
Sep 2, 2026
other
Elutia to Participate in the Lake Street Capital Markets 10th Annual Big Ideas Growth Conference & the H.C. Wainwright 28th Annual Global Investment Conference
Elutia to participate in Lake Street and H.C. Wainwright investor conferences, highlighting its work to address post-surgical infection.
Aug 15, 2026
listing_status
Listing Status: ELUT — Deficient (was Normal)
Elutia, Inc. - Class A Common Stock | Nasdaq Financial Status Indicator N → D
Aug 13, 2026
earnings_calendar
ELUT Q2 2026 Earnings Scheduled — 2026-08-13
Jul 31, 2026
earnings
Elutia to Report Second Quarter 2026 Financial Results on Thursday, August 13, 2026
Elutia to Report Second Quarter 2026 Financial Results on Thursday, August 13, 2026
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.15 | $-0.15–$-0.15 | -66.7% | -15.4% | 0↑ 1↓ | $0.0B | 1 |
| Next Q | $-0.13 | $-0.13–$-0.13 | -108.8% | +0.0% | 0↑ 1↓ | $0.0B | 1 |
| Current FY | $-0.63 | $-0.63–$-0.63 | -172.4% | -5.0% | 0↑ 1↓ | $0.0B | 1 |
| Next FY | $-0.54 | $-0.54–$-0.54 | 14.3% | -3.8% | 0↑ 1↓ | $0.0B | 1 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.150 | — |
| 7d ago | $-0.130 | -0.020 |
| 30d ago | $-0.130 | -0.020 |
| 60d ago | $-0.130 | -0.020 |
| 90d ago | $-0.130 | -0.020 |
Institutional ownership
Which big funds own ELUT (from quarterly 13F filings) and who is adding or trimming.
18 institutional holders with $2.5M total value (2,518,712 shares) as of 2026-Q2. Top holders: VANGUARD, GEODE, Corient. Net buying activity: 4 institutions added/increased vs 2 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | 1,142,575 | $1.1M | 45.4% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 285,229 | $279.4K | 11.3% | ADD +29.6% |
| Corient Private Wealth LP | 253,500 | $248.3K | 10.1% | — |
| RENAISSANCE TECHNOLOGIES LLC | 201,816 | $197.7K | 8.0% | DOUBLED +144.0% |
| VANGUARD FIDUCIARY TRUST CO | 172,446 | $169.0K | 6.8% | ADD +44.5% |
| BlackRock, Inc. | 167,857 | $164.4K | 6.7% | ADD +37.5% |
| CITADEL ADVISORS LLC | 123,505 | $121.0K | 4.9% | — |
| JANE STREET GROUP, LLC | 44,697 | $43.8K | 1.8% | TRIM -30.2% |
| NORTHERN TRUST CORP | 44,670 | $43.8K | 1.8% | ADD +61.5% |
| BROWN ADVISORY INC | 20,135 | $19.7K | 0.8% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 82,716 | 201,816 | +144.0% | $197.7K |
| VANGUARD FIDUCIARY TRUST CO | ADD | 119,345 | 172,446 | +44.5% | $169.0K |
| BlackRock, Inc. | ADD | 122,073 | 167,857 | +37.5% | $164.4K |
| JANE STREET GROUP, LLC | TRIM | 64,077 | 44,697 | -30.2% | $43.8K |
| NORTHERN TRUST CORP | ADD | 27,662 | 44,670 | +61.5% | $43.8K |
| UBS Group AG | NEAR_EXIT | 7,487 | 1,111 | -85.2% | $1.1K |
| JANE STREET GROUP, LLC | ADD | 47,266 | 64,077 | +35.6% | $67.3K |
| UBS Group AG | DOUBLED | 29 | 7,487 | +25717.2% | $7.9K |
| WELLS FARGO & COMPANY/MN | DOUBLED | 1,600 | 5,000 | +212.5% | $5.3K |
| BNP PARIBAS FINANCIAL MARKETS | TRIM | 7 | 3 | -57.1% | $3.00 |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
7 insiders, 29 transactions. Net $95.0K — $95.0K bought, $0.00 sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 10, 2026 | Mills C Randal | PRESIDENT AND CEO | EXERCISE | 27,083 | — | — |
| Sep 10, 2026 | Williams Michelle LeRoux | CHIEF SCIENTIFIC OFFICER | EXERCISE | 12,500 | — | — |
| Sep 10, 2026 | Ferguson Matthew | CHIEF FINANCIAL OFFICER | EXERCISE | 12,500 | — | — |
| Sep 10, 2026 | Ferguson Matthew | CHIEF FINANCIAL OFFICER | TAX W/H | 4,486 | $0.8000 | $3.6K |
| Sep 10, 2026 | Mills C Randal | PRESIDENT AND CEO | TAX W/H | 9,718 | $0.8000 | $7.8K |
| Sep 10, 2026 | Williams Michelle LeRoux | CHIEF SCIENTIFIC OFFICER | TAX W/H | 4,269 | $0.8000 | $3.4K |
| Jun 21, 2026 | Mills C Randal | PRESIDENT AND CEO | EXERCISE | 22,473 | — | — |
| Jun 21, 2026 | Mills C Randal | PRESIDENT AND CEO | TAX W/H | 8,064 | $1.06 | $8.5K |
| Jun 11, 2026 | NEELS GUIDO J | Director | AWARD | 106,393 | — | — |
| Jun 11, 2026 | Makes Brigid | Director | AWARD | 106,393 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for ELUT.
Shares short
8,223
Settlement Sep 15, 2026
Change vs prior
-51.5%
Semi-monthly cycle
Days to cover
1.0
At avg daily volume
Of shares outstanding
≈0.0%
Estimate — not % of float
All ELUT filing & press-release reports (4)
- PRESS-RELEASE reportJul 31, 2026
- 8-K reportJun 16, 2026
- 8-K reportMay 14, 2026
- 8-K reportMar 11, 2026